While treatment with trastuzumab, pertuzumab and their combination was not toxic to the HER2-negative breast cancer cell line HC1806 after 24 or 48 h, lapatinib and tucatinib showed toxic effects after 48 h of treatment at a concentration of 5,000 ng/mL. This evidence concerns the gene ERBB2 and breast carcinoma.